source
- Detalimogene Voraplasmid Achieves 54% Complete Response in BCG-Unresponsive Bladder CancerA clinical study of detalimogene voraplasmid reported a 54% complete response rate in patients with heavily pretreated, BCG‑unresponsive non‑muscle‑invasive bladder cancer that also had carcinoma i…
- Candel Therapeutics shares 20-month follow-up data for its prostate cancer candidate ahead of FDA filingCandel Therapeutics announced that it has completed a long-term follow‑up study of patients treated with its prostate cancer drug. The data extend to about 20 months after treatment and are intende…Endpoints · 3mo agoPositive readoutPositive